AG真人官方

PLEASANTON, Calif., May 14, 2025 /PRNewswire/ --聽听(狈补蝉诲补辩: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies. As part of the settlement, 10x expects that Bruker will pay $68 million in equal quarterly installments between the third quarter of 2025 and the second quarter of 2026, as well as ongoing royalties on sales of its spatial biology products through the life of the licensed patents.聽

"At 10x, we've always believed that bold, original science must be protected, not just for the benefit of a company, but for the entire scientific ecosystem," said Serge Saxonov, CEO of 10x Genomics. "It is our responsibility to defend our intellectual property to fuel innovations that will advance science and human health. We are very happy with the outcome and its validation of our strategy. It reinforces our deep commitment to innovation, bringing great products to market and supporting our customers every step of the way."

Eric Whitaker, Chief Legal Officer added, "This settlement really demonstrates the value of 10x's broad intellectual property portfolio and the fundamental importance of those inventions for spatial biology. We're pleased to conclude these matters on strong terms that support our mission and allow us to continue to invest in future breakthroughs."

The settlement includes global patent cross-licenses and a complete withdrawal of all legal proceedings, including those in the United States, Germany and before the European Unified Patent Court.

About 10x Genomics

10x Genomics聽is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit or connect with us on , , , or .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and the anticipated impacts of the settlement and license agreements with Bruker. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-Q for the fiscal quarter ended March 31, 2025 and 10-K for the fiscal year ended December 31, 2024 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

Investors: [email protected]
Media: [email protected]

View original content to download multimedia:

SOURCE 10x Genomics, Inc.